Marek Trněný, MD, PhD of the Charles University, Prague, Czech Republic highlights developments in mantle cell lymphoma (MCL) over the last 15 years. Prof. Trněný first highlights the progress in terms of outcome with the introduction of rituximab, stem cell transplant, and minimal residual disease (MRD) levels as markers. Nowadays, we have entered into a new era with targeted therapies based on the data with ibrutinib and lenalidomide and while there is hope that we can improve the outcome, there are still many questions. One of them is how to overcome resistance, for example in the case of ibrutinib. Another question is how to find the patients who are at risk of failing treatment and how to sequence the therapy. Prof. Trněný brings up the question if it is time to skip to stem cell transplant for young patients in first-line.
Recorded at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.